Midbrain Dopamine Neuron Differentiation via Controlled Culture Conditions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for directing the differentiation of embryonic and somatic stem cells into lineage-specific dopamine neurons for treating neurodegenerative diseases, such as Parkinson's, face limitations in therapeutic efficacy and safety, including the risk of tumor formation and limited capability to restore neuronal function in vivo.
Innovation Solution
The development of novel culture conditions and compositions that enable the directed differentiation of human pluripotent stem cells into midbrain fate FOXA2+LMX1A+TH+dopamine (DA) neurons, using a kit comprising specific signaling inhibitors and activators, which results in high purity and functionality of DA neurons capable of engrafting in vivo and providing dopamine neuronal function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If embryonic and somatic stem cells are used for treating neurodegenerative diseases, then cell replacement therapy can be provided, but the capability to restore neuronal function in vivo is limited and tumor formation risk increases
Solution Approach 1:
The patent applies parameter changes by modifying the differentiation conditions and culture parameters of stem cells to guide them toward specific neuronal lineages. By controlling differentiation parameters and using specific culture conditions, the patent directs stem cell differentiation into desired neuronal types while preventing uncontrolled proliferation that leads to tumor formation.
Solution Approach 2:
The patent segments the differentiation process into distinct stages and pathways, guiding stem cells through controlled differentiation steps toward specific neuronal subtypes. This segmentation allows for precise control over cell fate determination, ensuring cells differentiate into functional neurons rather than forming tumors.
2Reliability
If stem cells are differentiated into lineage-specific dopamine neurons, then therapeutic potential for Parkinson's disease increases, but manufacturing complexity and process control difficulty increase
Solution Approach 1:
The patent applies preliminary action by pre-establishing optimized differentiation protocols and culture conditions before actual stem cell differentiation. By pre-defining the differentiation pathway and conditions, the patent simplifies the complex process of generating dopamine neurons from stem cells, making it more controllable and reproducible.
Solution Approach 2:
The patent uses parameter changes to control differentiation by adjusting culture conditions, growth factors, and signaling molecules at specific stages. This systematic parameter control reduces the complexity of the differentiation process while maintaining high therapeutic potential for generating functional dopamine neurons.
3Reliability
If stem cells are differentiated into functional dopamine neurons with high purity, then engraftment capability improves, but differentiation time and process duration increase
Solution Approach 1:
The patent applies continuity of useful action by maintaining continuous differentiation signals and culture conditions that steadily drive stem cells toward the desired neuronal phenotype. This continuous action ensures high purity functional dopamine neurons are generated efficiently, improving engraftment capability while optimizing the differentiation timeline.
Data Source
AI summary
The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC) in addition to nonembryonic human induced pluripotent stem cells (hiPSC), somatic stem cells, stem cells from patients with a disease, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC into floor plate midbrain progenitor cells and then further into large populations of midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons using novel culture conditions. The midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons made using the methods of the present invention are further contemplated for various uses including, but not limited to, use in in vitro drug discovery assays, neurology research, and as a therapeutic to reverse disease of, or damage to, a lack of dopamine neurons in a patient. Further, compositions and methods are provided for differentiating midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons from human pluripotent stem cells for use in disease modeling, in particular Parkinson's disease. Additionally, authentic DA neurons are enriched for markers, such as CD142, and A9 type neuronal cells.